title: Aspirin-induced small bowel injuries and the preventive effect of rebamipide.
abstract: OBJECTIVE
  To evaluate the influence of taking low-dose aspirin for 4 wk on small intestinal complications and to examine the preventive effect of rebamipide.
  
  
  METHODS
  This study was conducted as a single-center, randomized, double-blind, cross-over, placebo-controlled study. Eleven healthy male subjects were enrolled. Each subject underwent video capsule endoscopy after 1 and 4 wk of taking aspirin and omeprazole, along with either rebamipide or placebo therapy. The primary endpoint was to evaluate small bowel damage in healthy subjects before and after taking low-dose aspirin for 4 wk.
  
  
  RESULTS
  The number of subjects with mucosal breaks (defined as multiple erosions and/or ulcers) were 1 at 1 wk and 1 at 4 wk on the jejunum, and 6 at 1 wk (P = 0.0061) and 7 at 4 wk on the ileum (P = 0.0019). Rebamipide significantly prevented mucosal breaks on the ileum compared with the placebo group (P = 0.0173 at 1 wk and P = 0.0266 at 4 wk).
  
  
  CONCLUSIONS
  Longer-term, low-dose aspirin administration induced damage in the small bowel. Rebamipide prevented this damage, and may be a candidate drug for treating aspirin-induced small bowel complications.
authors.affiliation: Department of General Medicine and Gastroenterology, Faculty of Medicine, Oita University, Yufu, Oita 879-5593, Japan. mizkaz0809@oita-u.ac.jp
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Mizukami
authors.forename: Kazunari
authors.initials: K
authors.lastname: Murakami
authors.forename: Takashi
authors.initials: T
authors.lastname: Abe
authors.forename: Kunimitsu
authors.initials: K
authors.lastname: Inoue
authors.forename: Masahiro
authors.initials: M
authors.lastname: Uchida
authors.forename: Tadayoshi
authors.initials: T
authors.lastname: Okimoto
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kodama
authors.forename: Toshio
authors.initials: T
authors.lastname: Fujioka
mesh_terms: D000328:Adult; D000368:Aged; D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects*; D053704:Capsule Endoscopy; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006801:Humans; D007410:Intestinal Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D007413:Intestinal Mucosa / Q000187:drug effects / Q000293:injuries / Q000473:pathology; D007421:Intestine, Small / Q000187:drug effects* / Q000293:injuries* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010919:Placebos / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D010919:Placebos; D015363:Quinolones; D009853:Omeprazole; C052785:rebamipide; D000409:Alanine; D001241:Aspirin